Pacific Edge cancer test heads to Australia

Last updated 12:14 28/03/2011
PEB 0.500 0.00 0.00%
PEB

Click for a detailed chart

Relevant offers

Industries

Kiwibank suffers growing pains as it splits from restructured NZ Post Bill English slams NZ Super Fund for chief executive's 36 per cent pay increase The very real heartbreak of being rejected from your dream job Webstock technology conference brings high drama to the stage of the St James Spark seeks injunction to prevent Sky/Vodafone 'fait accompli' 'Spy doll' pulled from shelves in Germany Beauty salon fined after using banned substance to apply acrylic nails Oxford professor sees entrepreneurship and science hand-in-hand Mondelez's global $4 billion cost-cutting drive behind Dunedin Cadbury factory closure Government is 'wasting money' on oil companies who have already ditched NZ - Green MP

Dunedin-based biomedical company Pacific Edge has signed an agreement with Australian health care provider Healthscope to market its test for the detection of bladder cancer.

Under the deal, Healthscope Pathology would market and offer laboratory services to urologists and general practitioners for the detection of bladder cancer using Cxbladder in Australia, Pacific Edge said today.

Pacific Edge would provide services to New Zealand urologists and GPs through its subsidiary Pacific Edge Diagnostics NZ, with its diagnostic laboratory based in Dunedin.

It would retain the rights to the rest of the world for the marketing of Cxbladder.

Terms of the licence agreement were confidential.

Cxbladder was a non-invasive, accurate test that enabled the early detection of bladder cancer from a small volume of urine, Pacific Edge said.

It provided a quick, cost effective and accurate measure of the presence of the cancer, and could reduce reliance on the need for invasive tests such as cystoscopy.

Products in development and in clinical trials included tools for detecting and managing gastric, bladder, colorectal, endometrial cancers and melanoma, Pacific Edge said.

Its shares were up 0.5c by late morning to 20c.

Ad Feedback

- NZPA

Special offers

Featured Promotions

Sponsored Content